![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ADAMTS12 |
Gene summary for ADAMTS12 |
![]() |
Gene information | Species | Human | Gene symbol | ADAMTS12 | Gene ID | 81792 |
Gene name | ADAM metallopeptidase with thrombospondin type 1 motif 12 | |
Gene Alias | PRO4389 | |
Cytomap | 5p13.3-p13.2 | |
Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | D6REX0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
81792 | ADAMTS12 | ATC11 | Human | Thyroid | ATC | 2.49e-06 | 5.02e-01 | 0.3386 |
81792 | ADAMTS12 | ATC12 | Human | Thyroid | ATC | 3.84e-45 | 1.03e+00 | 0.34 |
81792 | ADAMTS12 | ATC13 | Human | Thyroid | ATC | 5.47e-22 | 3.48e-01 | 0.34 |
81792 | ADAMTS12 | ATC2 | Human | Thyroid | ATC | 3.71e-05 | 4.34e-01 | 0.34 |
81792 | ADAMTS12 | ATC3 | Human | Thyroid | ATC | 5.52e-09 | 4.91e-01 | 0.338 |
81792 | ADAMTS12 | ATC4 | Human | Thyroid | ATC | 1.19e-64 | 1.35e+00 | 0.34 |
81792 | ADAMTS12 | ATC5 | Human | Thyroid | ATC | 6.51e-18 | 3.77e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003158928 | Thyroid | ATC | cell-substrate adhesion | 195/6293 | 363/18723 | 1.58e-15 | 1.17e-13 | 195 |
GO:0007160111 | Thyroid | ATC | cell-matrix adhesion | 128/6293 | 233/18723 | 1.49e-11 | 5.41e-10 | 128 |
GO:003019812 | Thyroid | ATC | extracellular matrix organization | 152/6293 | 301/18723 | 8.63e-10 | 2.24e-08 | 152 |
GO:004306212 | Thyroid | ATC | extracellular structure organization | 152/6293 | 302/18723 | 1.17e-09 | 2.94e-08 | 152 |
GO:004522912 | Thyroid | ATC | external encapsulating structure organization | 152/6293 | 304/18723 | 2.11e-09 | 5.08e-08 | 152 |
GO:006056222 | Thyroid | ATC | epithelial tube morphogenesis | 156/6293 | 325/18723 | 4.48e-08 | 8.14e-07 | 156 |
GO:009028721 | Thyroid | ATC | regulation of cellular response to growth factor stimulus | 140/6293 | 304/18723 | 3.91e-06 | 4.33e-05 | 140 |
GO:004801212 | Thyroid | ATC | hepatocyte growth factor receptor signaling pathway | 12/6293 | 13/18723 | 1.85e-05 | 1.69e-04 | 12 |
GO:003461228 | Thyroid | ATC | response to tumor necrosis factor | 116/6293 | 253/18723 | 3.22e-05 | 2.68e-04 | 116 |
GO:00020624 | Thyroid | ATC | chondrocyte differentiation | 54/6293 | 106/18723 | 1.67e-04 | 1.14e-03 | 54 |
GO:00614484 | Thyroid | ATC | connective tissue development | 112/6293 | 252/18723 | 2.08e-04 | 1.38e-03 | 112 |
GO:000315825 | Thyroid | ATC | endothelium development | 66/6293 | 136/18723 | 2.16e-04 | 1.42e-03 | 66 |
GO:007135627 | Thyroid | ATC | cellular response to tumor necrosis factor | 102/6293 | 229/18723 | 3.52e-04 | 2.18e-03 | 102 |
GO:00031598 | Thyroid | ATC | morphogenesis of an endothelium | 13/6293 | 20/18723 | 4.03e-03 | 1.73e-02 | 13 |
GO:00611548 | Thyroid | ATC | endothelial tube morphogenesis | 13/6293 | 20/18723 | 4.03e-03 | 1.73e-02 | 13 |
GO:00717726 | Thyroid | ATC | response to BMP | 72/6293 | 165/18723 | 4.50e-03 | 1.86e-02 | 72 |
GO:00717736 | Thyroid | ATC | cellular response to BMP stimulus | 72/6293 | 165/18723 | 4.50e-03 | 1.86e-02 | 72 |
GO:00512163 | Thyroid | ATC | cartilage development | 81/6293 | 190/18723 | 5.70e-03 | 2.30e-02 | 81 |
GO:007055513 | Thyroid | ATC | response to interleukin-1 | 63/6293 | 143/18723 | 5.82e-03 | 2.35e-02 | 63 |
GO:000910011 | Thyroid | ATC | glycoprotein metabolic process | 153/6293 | 387/18723 | 7.90e-03 | 3.06e-02 | 153 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ADAMTS12 | SNV | Missense_Mutation | novel | c.2302G>A | p.Ala768Thr | p.A768T | P58397 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-DD-AACX-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
ADAMTS12 | SNV | Missense_Mutation | novel | c.4427N>A | p.Ala1476Asp | p.A1476D | P58397 | protein_coding | deleterious(0.03) | possibly_damaging(0.609) | TCGA-DD-AAEH-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
ADAMTS12 | SNV | Missense_Mutation | c.77A>G | p.Tyr26Cys | p.Y26C | P58397 | protein_coding | tolerated_low_confidence(0.12) | benign(0) | TCGA-ED-A5KG-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
ADAMTS12 | SNV | Missense_Mutation | novel | c.1294N>C | p.Trp432Arg | p.W432R | P58397 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-RC-A6M4-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ADAMTS12 | SNV | Missense_Mutation | novel | c.4579A>G | p.Asn1527Asp | p.N1527D | P58397 | protein_coding | tolerated(0.07) | possibly_damaging(0.478) | TCGA-ZP-A9CY-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ADAMTS12 | deletion | In_Frame_Del | novel | c.298_300delNNN | p.Lys100del | p.K100del | P58397 | protein_coding | TCGA-QA-A7B7-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | PD | ||
ADAMTS12 | SNV | Missense_Mutation | c.3047N>A | p.Pro1016Gln | p.P1016Q | P58397 | protein_coding | tolerated(0.65) | benign(0) | TCGA-05-4249-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ADAMTS12 | SNV | Missense_Mutation | c.4342G>T | p.Val1448Leu | p.V1448L | P58397 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-05-4250-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
ADAMTS12 | SNV | Missense_Mutation | c.3140N>A | p.Ala1047Glu | p.A1047E | P58397 | protein_coding | tolerated(0.7) | benign(0.112) | TCGA-05-4382-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
ADAMTS12 | SNV | Missense_Mutation | novel | c.854C>A | p.Pro285Gln | p.P285Q | P58397 | protein_coding | deleterious(0) | possibly_damaging(0.897) | TCGA-05-4396-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |